INITIAL GOALS

Operationalize GBM AGILE into a self-sustaining
engine of therapeutic and biomarker development
for patients with GBM.
Finance the launch and ongoing activity of new
GBM-focused therapies developed through
GBM AGILE.
Use GBM AGILE as a model for developing an efficient
framework for the discovery and development of
therapies and biomarkers for other rare and deadly diseases.
Randall Garnick Photography, National Brain Tumor Society

LEADERSHIP

The Global Coalition for Adaptive Research (GCAR) is an international partnership

The Global Coalition for Adaptive Research (GCAR) is an international partnership comprised of some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary—the patient—is supported in the fight against rare and deadly diseases.

READ MORE

GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma.

GBM AGILE is changing the IDEA of clinical trials

Innovative – Next-generation trial that will lower cost of development and speed progress.

Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.

Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug's effectiveness.

Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
LEARN MORE

NEWS

Dr. W.K. Alfred Yung Addresses Members of U.S. Congress at Glioblastoma Event Hosted by NBTS, Senator Lindsey Graham
May 16, 2018  |  National Brain Tumor Society
Global Coalition for Adaptive Research Launches to Speed the Discovery & Development of Cures for Patients with Rare & Deadly Diseases
April 16, 2018  |  BusinessWire
Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?
March 8, 2018  |  Harvard Business School
W.K. Alfred Yung, M.D. – Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy
FEBRUARY 12, 2018  |  UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Dr. Brian M. Alexander – Kraft Precision Medicine Accelerator has met with the US Food and Drug Administration to Discuss Standardizing Platform Methodologies
January 15, 2018  |  Harvard Business School
Joe Biden Recognizes Dr. W.K. Alfred Yung on The View
December 13, 2017  |  ABC’s ‘The View’
Advancing Oncology Platform Trials
December 12-13, 2017  |  Dr. Brian M. Alexander, MIT Next Wave Forum 2017
Dr. Webster K. Cavenee Elected to the Chinese Academy of Engineering
November 28, 2017  |  Chinese Academy of Engineering
Dr. Brian M. Alexander – Adaptive Platform Trials: The Clinical Trial of the Future?
September 26, 2017  |  Ariel D. Stern and Sarah Mehta, Harvard Business Review
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
September 20, 2017  |  Dr. Brian M. Alexander, Dr. Sujuan Ba, Dr. Webster Cavenee, Dr. Timothy F. Cloughesy, Dr. W.K. Alfred Yung - American Association for Cancer Research
ALL NEWS

GET INVOLVED

CONTACT US

For additional information about GCAR and to learn how you can collaborate with us, please contact:
GENERAL INQUIRIES
MEDIA INQUIRIES